<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991198</url>
  </required_header>
  <id_info>
    <org_study_id>IFLOTDO002</org_study_id>
    <nct_id>NCT00991198</nct_id>
  </id_info>
  <brief_title>The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage</brief_title>
  <official_title>The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aria Aesthetics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aria Aesthetics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs
      of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical
      products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety)
      utilizing the regimen of products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin grading evaluation of photodamage</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>stratum corneum hydration (skin capacitance)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bioinstrumental assessment of skin &quot;melanin&quot; lightening, and lesional erythematous sites</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bioinstrumental assessment of skin texture, scaliness (desquamation)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>punch biopsy histopathologic examination (H&amp;E, and immunohistochemistry for Aquaporin 3, and Filaggrin)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RT-PCR collagenase , and hypoxia-inducible factor-1 alpha</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>product performance</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Rosacea</condition>
  <condition>Acne Vulgaris</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Seborrheic Dermatitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aria Regimens 0.5% conc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aria Regimen (5 products) 0.25% conc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aria Regimen Control without O2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical oxygen</intervention_name>
    <description>0.5% concentration of Topical oxygen</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical oxygen</intervention_name>
    <description>0.25% concentration topical oxygen</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>no O2</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be female, 25-60 years old in good general health;

          -  Subjects must be Fitzpatrick Types I, II, III, IV, V

          -  Subjects must be willing to forgo the use of facial cosmetics (e.g. facial
             moisturizers,creams, foundations, blush, etc.) during the course of the study.

          -  Subjects may ONLY use facial regimen of products provided by sponsor(lipstick, lip
             gloss, and eye mascara permitted).

        Exclusion Criteria:

          -  Known sensitivity to any of the test material ingredients.

          -  Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen,
             corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose
             drops and/or eye drops are permitted) (one-8lmg or 325mg aspirin okay) (birth control
             is okay but needs to be reported).

          -  Use of topical OTC/Rx drugs or other cosmetics at the test sites.

          -  Immunological disorders such as HIV positive and systemic lupus erythematosus
             (interview only)

          -  Participation in any clinical study within the last four weeks.

          -  Pregnant or lactating women (interview only).

          -  Damaged skin in or around test sites (including sunburn, uneven skin tones, tattoos,
             scars or other disfiguration of the test site).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoe D Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Consultants Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Consultants Inc</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Larry Rheins, PhD/President</name_title>
    <organization>Aria Aesthetics, Inc.</organization>
  </responsible_party>
  <keyword>Topically dissolved oxygen</keyword>
  <keyword>inflammatory cutaneous disease</keyword>
  <keyword>rosacea</keyword>
  <keyword>acne vulgaris</keyword>
  <keyword>atopic dermatitis</keyword>
  <keyword>seborrheic dermatitis</keyword>
  <keyword>photodamage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Acne Vulgaris</mesh_term>
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Dermatitis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

